Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

The trial will begin enrolling US participants early next year, with topline data expected in the second half of the year.

The lift is based on new research showing that the previous adverse effects in laboratory rats may not have been caused by ...

Monday, the FDA removed partial clinical holds on Rezolute, Inc.’s (NASDAQ:RZLT) RZ358 (ersodetug), a potential treatment for ...

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Rezolute (RZLT – Research Report), retaining the price target of $7.00.

Rezolute (NASDAQ:RZLT) shares gained 13% Monday morning as the U.S. FDA lifted its partial clinical hold on the firm's ...

Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company developing a novel therapy to treat hyperinsulinism (HI), ...

Rare disease biotech Rezolute recently announced that the FDA has lifted the partial clinical hold on RZ358 (ersodetug), a novel therapy in development for the treatment of low blood sugar ...

Abbott launched an over-the-counter continuous glucose monitoring system, Lingo, for adults not on insulin -- the second such ...

The FDA concluded that the liver toxicity observed was likely specific to a particular type of rats called Sprague Dawley, ...

The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital ...

FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S.Phase 3 study for ...